Although the vast majority of children don't end up in the hospital for Covid-19, as of Saturday, the number of children who were newly hospitalized saw a 21% increase week over week, according to the CDC.
Parents and pediatricians alike are eager to have children vaccinated as schools reopen, but the process may take awhile longer.
The FDA asked Pfizer and Moderna to double the number of children ages 5 to 11 in clinical trials, while also asking for six months of follow-up safety data. For adults, the FDA only required two months of follow-up data.
Many experts have criticized the FDA for this decision, such as Dr. Yvonne Maldonado, who claims families "don't have the luxury of being able to sit back and wait for additional data like this to roll in."
Due to this timeframe, data for children ages 5 to 11 could come sometime in September. Depending on the results, Pfizer told CNN it could ask the FDA to authorize the vaccine that same month.
Meanwhile, data for 2-to-5-year-olds could arrive soon after. For the youngest children, Pfizer said it could potentially get data in October or November, and shortly thereafter ask the FDA to authorize emergency use.
However, authorization from the FDA can take several weeks, meaning a vaccine for younger children likely won't be available until late fall or even next year.
Moderna told CNN it expects data later this year or toward the beginning of 2022. There may also be interim data at various stages in the trial, but that timeline is hard to predict.
Additionally, Johnson & Johnson told CNN that it has used its small trial with 16- and 17-year-olds from earlier in the year to design four late stage studies for younger children, and the company is in "active discussions with regulatory authorities regarding our development plan and trial designs." The company anticipates those trials will start in the fall.
Read more about a possible timeline for vaccinating children here.